KLOW Peptide: What's in the GLOW + KPV Blend and What the Evidence Shows

The KLOW peptide is a four-peptide blend that has become one of the most searched names in aesthetic and regenerative peptide circles. It combines the three peptides of the GLOW stack — GHK-Cu, BPC-157, and TB-500 — with a fourth, KPV. This article breaks down what is actually in a KLOW preparation, why each component is included, what the published evidence does and does not support, and where each ingredient stands with the FDA as of mid-2026.

The short version: every claim about KLOW is a claim about its individual components. There are no published human trials of the KLOW blend itself.

What Is the KLOW Peptide?

KLOW is a marketplace name, not a pharmacopeial one. It is generally understood as the GLOW peptide stack with KPV added — "K" for KPV. There is no monograph defining it, no standardized ratio between the four peptides, and no single reference formulation. Two products sold as "KLOW" can differ in the amount of each component, the salt form used, and whether the peptides are combined in one vial or supplied separately.

That variability is the first practical point for a prescriber: the name tells you which molecules are supposed to be present, not how much of each or in what form.

Why Each Component Is Included

GHK-Cu: The Skin-Remodeling Anchor

GHK-Cu is an endogenous human tripeptide bound to copper. Its published research centers on extracellular matrix remodeling — stimulation of collagen, elastin, and glycosaminoglycan synthesis alongside regulation of matrix metalloproteinases. It is the component with the most direct clinical connection to skin appearance, which is why it anchors both GLOW and KLOW.

BPC-157: Angiogenic and Repair Signaling

BPC-157 is included for tissue-repair signaling. Its research base is largely animal work describing angiogenesis, nitric-oxide pathway involvement, and protection of gastrointestinal and connective tissue. FDA's July 2026 briefing noted that dose-response relationships were not established and that human safety data are insufficient.

TB-500: Cell Migration

TB-500 corresponds to a fragment of thymosin β-4, a protein involved in actin regulation and cell migration. It is included on the theory that it supports the cellular movement that tissue repair depends on. FDA found no medical literature in which TB-500 was administered to patients, and cited an in-vitro study in which TB-500 did not induce wound healing in scratch-wounded fibroblast cultures.

KPV: The Anti-Inflammatory Addition

KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of α-melanocyte-stimulating hormone. Nonclinical studies suggest anti-inflammatory activity, possibly through inhibition of inflammatory cytokines and NF-κB-driven signaling. Its addition is the entire difference between GLOW and KLOW: the rationale offered is that dampening inflammation complements the remodeling and repair signaling of the other three. FDA found no human data for KPV by any route. For the research that does exist, see our KPV mechanism overview.

What the Evidence Shows — and What It Doesn't

No Trials of the Blend

We are not aware of any published human study of the KLOW combination. The rationale for combining the four peptides is mechanistic: each is described as acting on a different part of the repair and remodeling process, so the combination is assumed to be complementary. That assumption has not been tested.

Component Evidence Is Uneven

The four components sit at very different evidence levels. GHK-Cu has controlled and open-label topical studies reporting improvements in skin density, elasticity, and fine-line depth, though several were industry-sponsored and effect sizes varied with formulation. BPC-157 has animal data and one small exploratory human trial in an unrelated indication. TB-500 and KPV have no identified human efficacy data.

Combination Questions Nobody Has Answered

Putting four peptides in one preparation raises questions that single-peptide research does not address: whether the peptides remain stable together, whether the copper in GHK-Cu interacts with the other components in solution, and whether combined injection changes tolerability or immunogenicity. None of these has been characterized in the published literature.

KLOW vs GLOW

The only compositional difference is KPV. A prescriber choosing between them is really deciding whether the anti-inflammatory rationale for KPV justifies adding a fourth peptide with no human data and an unfavorable FDA proposal. Our GLOW peptide stack guide covers the three-peptide version in detail.

Regulatory Status of KLOW's Components

At the July 23, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA proposed that BPC-157, TB-500, and KPV (free base and acetate forms) not be added to the 503A Bulks List, citing inadequate characterization and insufficient effectiveness and safety evidence. These are advisory-committee proposals rather than final rules, and none of the three was ever FDA-approved.

GHK-Cu is on a separate track: as of the site's July 2026 tracker it was scheduled for PCAC review before February 2027, with non-injectable routes previously under Category 1 evaluation. Our GHK-Cu FDA status update explains the dual-route history.

Because three of KLOW's four components face an unfavorable proposal, whether a 503A pharmacy can compound a KLOW-type preparation depends on current FDA determinations. Check the FDA peptide status tracker for the latest position on each component.

Dosing: Why There Is No Established KLOW Dose

There is no FDA-labeled dose, no dose-finding study, and no published protocol for the KLOW combination. Numbers circulating online come from vendors and forums, not from clinical evidence, and they cannot account for the ratio variability described above. Where a prescriber considers any component, dosing is prescriber-determined and should start from that component's own evidence — see GHK-Cu dosage, KPV half-life and dosing, and TB-500 half-life and dosing. For reconstitution arithmetic only, the peptide calculator converts vial strength and diluent volume into concentration.

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

Safety Considerations

• Copper handling. GHK-Cu delivers copper. Wilson's disease and other copper-handling disorders are a contraindication for systemic use; see GHK-Cu contraindications and safety.
• No human safety profile. FDA found insufficient human safety information for BPC-157, TB-500, and KPV.
• Injectable immunogenicity. FDA flagged potential immunogenicity from aggregation and peptide-related impurities for injectable peptides lacking human data.
• Pregnancy and lactation. No supporting data for any component.
• Sourcing. Products labeled "research use only" are not compounded medications and carry no quality assurance for human use.

Availability Depends on the Prescriber and the 503A Partner

Whether any KLOW component is appropriate for a patient is a prescriber's decision, and whether it can be compounded depends on the partner pharmacy and the regulatory status at the time. Newtropin connects licensed providers with a licensed 503A compounding partner; it does not prescribe, compound, or dispense. Providers can review the provider pathway or see how these compounds fit the broader peptides for skin hub.

Frequently Asked Questions

What is the KLOW peptide?

KLOW is a blend of four peptides — GHK-Cu, BPC-157, TB-500, and KPV. It is the GLOW stack with KPV added. The name is a marketplace label with no standardized formulation, so component amounts vary by source.

What is the difference between KLOW and GLOW?

KPV. GLOW contains GHK-Cu, BPC-157, and TB-500; KLOW adds KPV, an anti-inflammatory tripeptide derived from α-MSH.

Is there a standard KLOW dose?

No. There is no FDA-labeled dose, no dose-finding study, and no published protocol for the blend. Any dosing is prescriber-determined and based on each component's own evidence.

Is KLOW FDA-approved?

No. None of its four components is an FDA-approved drug. In July 2026 FDA proposed not adding BPC-157, TB-500, or KPV to the 503A Bulks List, and GHK-Cu was scheduled for PCAC review by February 2027.

Has KLOW been studied in humans?

We are not aware of any published human study of the KLOW combination. Evidence exists only at the level of individual components, and it is uneven — strongest for topical GHK-Cu and absent for TB-500 and KPV.